REVITALIST LIFESTYLE AND WELLNESS LTD announces it has signed a licensing partnership agreement with Awakn Life Sciences Corp. to implement their KARE® protocol for those suffering from Alcohol Use Disorder seeking sustained recovery measures focused on relapse prevention. Awakn's proprietary ketamine-assisted therapy for the treatment of Alcohol Use Disorder was developed and validated in a Phase II a/b trial, with results announced in the American Journal of Psychiatry in January 2022.

The trial delivered 86% abstinence over the six-month period post treatment versus 2% pre-trial and 25% in the current standard of care. Under the terms of the license agreement Awakn will provide access to the proprietary therapeutics and training by their Subject Matter Experts to the Revitalist providers. Revitalist will pay an annual licensing fee and revenue share for clients seeking services through Revitalist and Awakn's partnership.